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Abstract
Prion infections cause inexorable, progressive neurological dysfunction and neurodegen-
eration. Expression of the cellular prion protein PrPC is required for toxicity, suggesting the
existence of deleterious PrPC-dependent signaling cascades. Because group-I metabotro-
pic glutamate receptors (mGluR1 and mGluR5) can form complexes with the cellular prion
protein (PrPC), we investigated the impact of mGluR1 and mGluR5 inhibition on prion toxic-
ity ex vivo and in vivo. We found that pharmacological inhibition of mGluR1 and mGluR5
antagonized dose-dependently the neurotoxicity triggered by prion infection and by prion-
mimetic anti-PrPC antibodies in organotypic brain slices. Prion-mimetic antibodies increased
mGluR5 clustering around dendritic spines, mimicking the toxicity of Aβ oligomers. Oral
treatment with the mGluR5 inhibitor, MPEP, delayed the onset of motor deficits and moder-
ately prolonged survival of prion-infected mice. Although group-I mGluR inhibition was not
curative, these results suggest that it may alleviate the neurological dysfunctions induced by
prion diseases.
Author summary
Prion diseases are a result of ordered accumulation of the misfolded conformer of cellular
prion protein (PrPC), a GPI anchored protein expressed on the cell surface. Similar patho-
genetic principles operate in several other neurodegenerative diseases. Currently no dis-
ease-modifying therapies exist and the situation is compounded by a dearth of validated
therapeutic targets. In our present study, we have discovered that genetic ablation, or
pharmacological inhibition, of group-I (i.e. activating) metabotropic glutamate receptors
is beneficial against prion neurotoxicity in vitro and in vivo. Mice treated with these inhib-
itors exhibited impressive suppression of neurological signs and a delayed onset of the
symptoms. These results further suggest that activation of these metabotropic glutamate
receptors is a downstream event of prion replication and targeting these receptors could
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be a therapeutic option to alleviate the neurological symptoms, thereby ameliorating the
quality of life in patients having prion infection.
Introduction
The decisive event in the pathogenesis of prion diseases is the conversion of the normal cellular
prion protein (PrPC) into an aggregated conformational variant called PrPSc [1]. Expression of
PrPC at the cell surface is not only required for the self-propagation of prions, but also for
mediating the toxicity induced by PrPSc [2], a process that results in endoplasmic reticulum
(ER) stress and ultimately in impaired protein translation [3]. But how can PrPC, an extracellu-
lar GPI-linked protein, initiate intracellular central nervous system (CNS) toxicity? Most likely
this process requires mediation by transmembrane constituents. Indeed PrPC has been shown
to interact with transmembrane signal-transducing proteins [4] and disturbing these interac-
tions might lead to the neurotoxicity seen in prion diseases [5].
Among the proteins interacting with PrPC are glutamate receptors [6]. N-methyl-D-aspar-
tate receptors (NMDAR) are crucial regulators of glutamatergic transmission, and loss of both
synapses and neurons has been attributed to inappropriate NMDAR activation [7, 8]. Metabo-
tropic glutamate receptors (mGluRs) may also play a role in prion diseases. Changes in
mGluR1, leading to reduced expression levels of phospholipases, were observed in the cerebral
cortex of Creutzfeldt-Jakob disease (CJD) patients [9]. Also, impairment of the mGluR1/
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase 1 (PLC1)/protein kinase C (PKC)
signaling pathway has been observed in a murine model of BSE. Abnormal mGluR1 signaling
correlated with PrPSc deposition, histological changes, and clinical scores [10].
A role for group-I mGluRs is emerging in a multitude of CNS disorders including Fragile X
syndrome, ischemia, multiple sclerosis, amyotrophic lateral sclerosis, Huntington’s, and Par-
kinson’s disease [11–18]. In Alzheimer’s disease (AD), PrPC and mGluR5 may directly con-
tribute to disease manifestation and toxicity of amyloid-β (Aβ) aggregates. Aβ oligomers can
bind to PrPC at the cell surface [19] and form complexes that contain mGluR5 [20]. In a
mouse model of Aβ deposition, cognitive decline and synaptic alterations were rescued by
mGluR5 inhibition [21]. Furthermore, PrPC-mGluR5 coupling is involved in Aβ-mediated
inhibition of LTP and Aβ-facilitated LTD in vivo [22], and genetic ablation of mGluR5 reverses
disease-related memory deficits in a murine model of AD (APPswe/PS1ΔE9) [23]. In another
study, exposure of cortical APPswe/PS1ΔE9 neuronal cultures to Aβ oligomers upregulated
mGluR1 and PrPC α-cleavage, whereas activation of group-I mGluRs increased PrPC shedding
from the membrane [24]. In primary hippocampal neurons, membrane-bound Aβ oligomers
induce toxicity by promoting clustering of mGluR5 in synapses, resulting in elevated intracel-
lular calcium and synaptic failure [25]. All these studies suggest an involvement of group-I
mGluRs in the pathogenesis of AD. On the other hand, others have reported that neither PrPC
ablation nor overexpression had any effect on neurotoxicity in AD models [26–29]. As a possi-
ble explanation for these discrepancies, it has been suggested that only a limited oligomeric
fraction of Aβ [30] interacts with mGluR5 [31].
Here we focused on the role of group-I mGluR-PrPC interaction in prion disease. We
found that toxic prion-mimetic compounds increased mGluR5 clustering and accumulation at
dendritic heads, close to the synaptic source of glutamate. Moreover, pharmacological inhibi-
tion of mGluR1 and mGluR5, as well as genetic ablation of the Grm5 gene encoding mGluR5,
protected organotypic slice cultures against the toxicity of prions and of prion-mimetic
Group-1 metabotropic glutamate receptors and prion toxicity
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compounds. Finally, pharmacological inhibition of mGluR5 improved the neurological status
and, to some extent, the survival of prion-infected mice.
Results
Group-I mGluRs antagonists rescue prion-induced neurotoxicity in
organotypic slices
Cerebellar and hippocampal organotypic cultured slices (COCS and HOCS, respectively) [32,
33] prepared from PrPC overexpressing tga20 mice [34] can be infected with the Rocky Moun-
tain Laboratory (RML) strain of prions and undergo neurodegeneration after ca. 5 weeks [32].
The time course and extent of neurodegeneration can be measured by morphometric assess-
ment of the area of the cerebellar granule cell layer (CGL) immunoreactive to antibodies
against the neuronal NeuN antigen.
We inoculated COCS and HOCS with brain homogenate from CD1 mice that had been
infected with RML prions (passage #6, henceforth called RML6). For control, slices were inoc-
ulated with non-infectious brain homogenate (NBH) derived from healthy CD1 mice. Starting
at 21 days post infection, slices were treated with a range of concentrations of either N-cyclo-
hexyl-6-N-methylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM202074) [35], 2-methyl-6-
(phenylethynyl)-pyridine (MPEP) [36] or Mavoglurant (AFQ056) [37] which specifically
inhibit mGluR1 and mGluR5, respectively.
MPEP, AFQ056 and YM202074 prevented CGL loss in COCS at concentrations as low as
10 nM (Fig 1A and 1B) and 36 nM (Fig 1C, 1D, 1G and 1H), respectively. The protective effect
of YM202074 and MPEP was further confirmed in wild-type slices (S1A and S1B Fig).
Extremely high MPEP concentrations (3–10 μM) were not intrinsically toxic (S1C Fig) as pre-
viously reported [36], but failed to protect against prion toxicity in tga20 mice (S1C and S1D
Fig). Also in HOCS, prepared from 4–6 days old tga20 mice, MPEP significantly suppressed
neuronal loss after prion infection at concentrations as low as 36 nM (Fig 1E and 1F).
MPEP alleviates the clinical signs of prion disease in mice
The beneficial effects of mGluR5 inhibition ex vivo encouraged us to assess whether MPEP can
potentially rescue prion pathogenesis in vivo. C57BL/6J male mice were inoculated intracere-
brally with 3 or 5 log LD50 units of RML6 prions as described [38] and chronically treated with
MPEP. Control mice were inoculated with NBH. In order to record the neurological deficits
associated with prion disease, we utilized the rotarod behavioral test which measures a combi-
nation of motor performance, coordination and balance [39]. Rotarod performance was simi-
lar in RML6- and NBH-inoculated mice until 18 weeks following prion inoculation. Starting
from 19 weeks post inoculation, mice receiving control food showed a progressive decline in
rotarod performance. The performance of MPEP-treated mice declined, but less rapidly. This
improvement was lasting and detectable until the very late stages of the disease (22–23 weeks
post inoculation; Fig 2A and 2B), suggesting that the progression of the disease was delayed by
MPEP.
At very late time points, the general health status of all mice deteriorated to an extent that
made it impossible to accurately measure their rotarod performance and eventually required
euthanasia. Nevertheless, MPEP-treated mice showed a modest, though significant, prolonga-
tion of survival (Fig 2C and 2D). The median survival for untreated vs MPEP-treated RML6-i-
noculated C57BL/6J mice was, respectively, 183 vs 190 days post inoculation (dpi) after
injection with 3 log LD50 units of prions and 188 vs 195 dpi after inoculation with 5 log LD50
units (P = 0.0008 and 0.0231 respectively; log-rank test). Control mice injected with NBH and
Group-1 metabotropic glutamate receptors and prion toxicity
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treated with MPEP exhibited stable rotarod performance during the entire test period, up to
23 weeks post-injection (S2A Fig). No significant changes in average food and water consump-
tion were observed between control and treatment groups during the experiment (S2B Fig).
To determine the exposure of the brain to MPEP, mice treated with control and MPEP food
Fig 1. mGluR1/5 inhibition rescues prion neurotoxicity in organotypic slice cultures. (A-B) Treatment
with the mGluR5 inhibitor (MPEP) rescued neurodegeneration in tga20 RML6-treated COCS. (A)
Fluorescence micrographs of tga20 COCS. RML6-induced ablation of the cerebellar granular layer (CGL)
was significantly ameliorated by the mGluR5 inhibitor, MPEP. All scale bars: 500μm. (B) NeuN coverage in
tga20 COCS exposed to RML6 or NBH and treated with MPEP at 21–45 days post inoculation (dpi),
expressed as percentage of NBH samples. Each dot represents a pool of 4–10 slices cultured in the same
well. Data points are mean ± s.d.; one-way ANOVA followed by Dunnett’s post-hoc test. (C-D) Treatment with
the mGluR5 inhibitor AFQ056 (mavoglurant) also rescued neurodegeneration in tga20 RML6-treated COCS
(experimental conditions as in panels A-B). (E-F) Treatment with the mGluR5 inhibitor (MPEP) rescued
neurodegeneration in tga20 RML6-treated HOCS. (E) Fluorescence micrographs of tga20 HOCS, showing
ablation of hippocampal neurons induced by RML6 infection (middle), that is significantly ameliorated by
addition of the IC50 concentration of MPEP (36nM, 21–45 dpi, right). (F) Morphometry of the experiment
shown in panel E. (G) Treatment with the mGluR1 inhibitor (YM202074) rescued neurodegeneration in tga20
RML6-treated COCS. Experimental conditions were the same as in the panels above. (H) Morphometry of the
experiment shown in panel G; *: P < 0.05, **: P < 0.01, ***: P < 0.001; For (A), (C), (E) and (G) panels: Scale
bar is 500μm.
https://doi.org/10.1371/journal.ppat.1006733.g001
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were sacrificed at two time points, corresponding to the active and the inactive phase of the
mice across the circadian circle. The average brain-to-blood ratio for the MPEP concentration
was around 1, indicating good brain penetration of MPEP (S2C Fig, S1 Table).
mGluR5 and mGluR1 inhibitors protect against prion-mimetic antibodies
Antibody-derived molecules targeting the globular domain (GD) of PrPC (termed GDLs) are
acutely neurotoxic [40, 41] and activate similar cascades as bona fide prion infection [42]. Sin-
gle chain POM1 miniantibodies (scPOM1), fusion proteins containing only the variable
regions of the heavy (VH) and light chains (VL) of the antibody connected with a short linker
peptide, were previously shown to be sufficient to induce toxicity in COCS [41]. To investigate
if pharmacological inhibition of mGluR1 and mGluR5 rescues GDL toxicity, we exposed tga20
Fig 2. mGluR5 inhibition delays prion disease in wild-type mice. (A-B) MPEP improves motor performance in mouse models of prion disease.
Motor abilities of MPEP-treated and control C57BL/6J males were assessed by rotarod after i.c. innoculation with 3 log LD50 (A) and 5 log LD50 (B) units
of RML6 prions. Dot plots: latency to fall (seconds). Each dot corresponds to a mouse. Two-way ANOVA per each time point revealed a significant
difference between MPEP treated and MPEP untreated groups at 19-22wpi (*: P<0.05 and **: P<0.01) for mice injected with 3 log LD50 RML6 units
and at 21-23wpi (*: P<0.05 and **: P<0.001) for mice injected with 5 log LD50 RML6 units respectively, n = 10 mice per group. Shaded areas represent
standard deviations. (C-D) mGluR5 inhibition (MPEP treatment) significantly prolonged survival in mouse models of prion disease. Survival curves of
MPEP treated and MPEP untreated C57BL/6J males, inoculated i.c. with 3 log LD50 and 5 log LD50 units of RML6 prions respectively. (C) Mice
inoculated with 3 log LD50 RML6 units: MPEP untreated group, n = 10, median incubation time 183 days post inoculation (dpi). MPEP treated group,
n = 10, median incubation time 190 dpi; P = 0.0008; log-rank test. (D) Mice inoculated with 5 log LD50 RML6 units: MPEP untreated group, n = 10,
median incubation time: 188.5 dpi, P = 0.0008; MPEP treated group, n = 10, median incubation time: 195dpi, P = 0.0231; log-rank test.
https://doi.org/10.1371/journal.ppat.1006733.g002
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COCS to the GDL agent scPOM1, followed by YM202074, MPEP and AFQ056 treatments.
Treatment with scPOM1 led to almost complete CGL loss within 8 days of treatment. No CGL
loss occurred in control treatment where scPOM1 was blocked by pre-incubation with a molar
excess of recombinant PrP (recPrP). Treatment with MPEP significantly reduced CGL loss in
scPOM1-treated slices. As with prion infections, MPEP treatment (at concentrations as low
as 10 nM) was sufficient to rescue the loss of CGL, whereas high concentrations (1μM) did
not show protective activity (Fig 3A and 3B). Even lower MPEP concentrations (3nM) were
sufficient to rescue scPOM1-induced toxicity in COCS (S3E and S3F Fig). AFQ056 and
YM202074 treatment (at concentrations as low as 36nM) also significantly reduced the toxicity
of scPOM1 (Fig 3C, 3D, 3G and 3H) in COCS.
The protective effect of mGluR1 and mGluR5 inhibitors (YM202074 and MPEP respec-
tively) was further confirmed in wild-type slices. No additional effect was observed upon dou-
ble MPEP/YM202074 inhibition (S3A and S3B Fig). Similarly to COCS, HOCS treated with
scPOM1 exhibited conspicuous toxicity after 8 days of treatment. Neuronal loss was moni-
tored by morphometric analysis of NeuN immunofluorescence, and was readily visible in
GDL-treated samples, whereas the survival of hippocampal neurons exposed to scPOM1 (Fig
3E and 3F) was greatly increased by treatment with MPEP. In contrast, no protection was
observed upon treatment with the selective group III agonist L-2-amino-4-phosphonobutyrate
(L-AP4) [43] and the potent group II/III antagonist (RS)-α-Cyclopropyl-4-phosphonophenyl-
glycine (CPPG) [44] of metabotropic glutamate receptors (S3C and S3D Fig). Hence toxicity
of both infectious prions and prion-mimetic GDLs was prevented by pharmacological inhibi-
tion of mGluR1 or mGluR5.
Toxicity of prions and prion-mimetic antibodies in Grm5-/- mice
Cerebellar organotypic slice cultures from Grm5-/-, Grm5+/- and Grm5+/+ littermates were
treated with the anti-GD single-chain miniantibody scPOM1 [45], which acts as a prion-
mimetic compound. Exposure to scPOM1 led to the loss of cerebellar granular layer (CGL)
neurons in Grm5+/+ slices, but neither in Grm5-/- nor in Grm5+/- slices (Fig 4A and 4B). We
then inoculated cerebellar and hippocampal organotypic slice cultures from Grm5-/-, Grm5+/-
and Grm5+/+ littermates with RML6 prions or control NBH homogenate. In COCS, both
Grm5-/-and Grm5+/- slices are protected against RML6 toxicity (Fig 4C and 4D). In HOCS,
genetic ablation of mGluR5 was protective against prion-induced toxicity (Fig 4E and 4F).
To assess the role of mGluR5 in prion infections in vivo, we infected Grm5-/-, Grm5+/- and
Grm5+/+ littermates with RML6 prions (5 log LD50). In line with a recently published study
[46], no significant difference in survival was observed between Grm5-/-, Grm5+/- and Grm5+/+
mice (S4A Fig).
The latter finding was unexpected and prompted us to investigate the possibility of com-
pensatory mechanisms. Both group-I metabotropic glutamate receptors, mGluR1 and
mGluR5, can associate with PrPC and induce similar intracellular pathways [47] suggesting
functional redundancy between these two receptors. In order to detect a possible epistasis
between mGluR1 and mGluR5, we assessed mGluR1 and mGluR5 protein levels in cerebel-
lum, cortex and hippocampus of Grm5-/-, Grm5+/- and Grm5+/+ mice (S4C and S4D Fig).
At 10 days of age, mGluR5 expression was similar in cerebellum, hippocampus and cortex
as described [48], whereas mGluR1 was highest in the cerebellum (S4C Fig). Interestingly, we
observed an increased expression of mGluR1 in all the three tested regions of Grm5-/- brains.
We further assessed mGluR1 and mGluR5 levels at later time points (45–180 days). Expression
of mGluR5 decreased in all brain regions with increasing age, whereas expression of mGluR1
remained stable. However, we detected increased mGluR1 expression in Grm5-/- brains. In the
Group-1 metabotropic glutamate receptors and prion toxicity
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Fig 3. Group-I mGluR inhibition abolishes GDL toxicity in organotypic slice cultures. (A-B) Treatment
with the mGluR5 inhibitor (MPEP) rescued neurodegeneration in scPOM1-treated COCS from tga20 mice. (A)
Ablation of the cerebellar granular layer (CGL) after exposure of tga20 COCS to scPOM1, and amelioration by
MPEP. (B) NeuN morphometry of tga20 slices exposed to scPOM1 or control (scPOM1 blocked with recPrP)
and treated with MPEP at 14–28 days post exposure (dpe). (C) CGL ablation after exposure to scPOM1, and
amelioration by AFQ056. (D) NeuN morphometry of tga20 slices exposed to scPOM1 or control scPOM1
blocked with recPrP and treated with MPEP from 14–22 dpe. (E-F) Treatment with MPEP rescued
neurodegeneration in tga20 scPOM1-treated COCS. (E) Ablation of the hippocampal neuronal layer induced by
exposure of HOCS to scPOM1 (middle), and amelioration by MPEP. (F) NeuN morphometry of tga20 slices
exposed to scPOM1 or control (scPOM1 blocked with recPrP) and treated with MPEP from 14–22 dpe. (G-H)
Treatment with the mGluR1 inhibitor (YM202074) rescued neurodegeneration in tga20 scPOM1-treated COCS.
(G) Ablation of the CGL in COCS by exposure to scPOM1, and suppression of toxicity by the mGluR1
antagonist, YM202074. (H) NeuN morphometry of tga20 slices as in panel F, but treated with YM202074 (14–22
dpe). All scale bars: 500μm. For (B), (D), (F) and (H): NeuN relative signal intensity as percentage of scPOM1
+recPrP control samples. Each dot represents a pool of 7–10 cerebellar slices or 4–6 hippocampal slices
cultured in the same well; Data are presented as mean ± s.d.; One-way ANOVA followed by Dunnett’s post-hoc
test; **: P < 0.01, ***: P < 0.001.
https://doi.org/10.1371/journal.ppat.1006733.g003
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Fig 4. Grm5 ablation protects against GDL and prion-induced neurotoxicity in slice cultures. (A-B) scPOM1 induced
CGL profound neurotoxicity in Grm5+/+ slices. However, toxicity was much less pronounced in Grm5+/- and Grm5-/- slices. (B)
NeuN morphometry of Grm5+/- and Grm5-/- and Grm5+/+ slices exposed to scPOM1 or scPOM1 blocked with recPrP from 14–22
dpe. (C-D) CGL ablation induced by RML6 infection in control Grm5+/+ slices, and amelioration in Grm5+/- and Grm5-/- slices.
Slices were maintained in culture for 60 dpi. (E-F) Genetic ablation of Grm5 rescued prion-induced neurodegeneration in HOCS.
(E) Representative images of HOCS, showing ablation of the hippocampal neuronal layer induced by RML6 infection in control
Grm5+/+ slices, that is significantly ameliorated by the genetic deletion of Grm5 (Grm5-/- slices). Slices were maintained in culture
for 60 dpi. (F) NeuN morphometry of Grm5+/- and Grm5-/- and Grm5+/+ slices exposed to RML6 or NBH. RML6-induced
Group-1 metabotropic glutamate receptors and prion toxicity
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cortex, we observed increased expression of mGluR1 in samples from 45-day old Grm5-/- mice
compared to Grm5+/+ littermates (S4D Fig, middle right panel). In the hippocampus, we
observed increased expression of mGluR1 in samples from 90-day old Grm5-/- mice (S4D Fig,
bottom right panel) and in samples from both Grm5+/- and Grm5-/- 180-day old mice (S4D
Fig, lower right panel, lanes 7, 8 & 9 and quantification). In the cerebellum, we observed
increased expression of mGluR1 in samples from 90-day old Grm5-/- mice compared to wild-
type control littermates (S4D Fig, upper right panel).
We then tested whether treatment with MPEP also enhances the expression of mGluR1.
mGluR1 expression levels were assessed in whole-brain lysates from 1-year old control wild-
type mice, NBH-inoculated wild-type mice, and NBH-inoculated wild-type mice that received
MPEP food. However, no differences were observed in the mGluR1 expression levels between
the samples (S4B Fig), suggesting that compensatory Grm1 upregulation is developmentally
controlled.
PrPC interacts with both mGluR1 and mGluR5 in vivo
PrPC interacts with mGluR1 and mGluR5 [21, 47]. We confirmed these results by immunopre-
cipitating brain homogenates from wild-type (C57BL/6J) or Prnp knockout mice (Prnpo/o)
using antibody POM1 against PrPC, followed by Western blotting with antibodies to mGluR1
and mGluR5. The group-I mGluRs, which migrate as SDS-resistant oligomers at 250kDa [49],
were found to co-precipitate with PrPC (Fig 5A). When we blocked the antigen-recognition
domain of POM1 with recombinant PrP, mGluR1 and mGluR5 no longer co-precipitated
with PrPC (Fig 5A). Western blots of brain lysates (total extracts; TEs) did not reveal any
changes in the concentration of mGluR1 and mGluR5 protein between wild-type tga20 and
Prnpo/o homogenates (Figs 5A and S5A). In contrast, mGluR6 and mGluR2/3 did not co-pre-
cipitate, confirming the specificity of the interaction (S5B Fig).
The residues 91–153 of PrPC participate to the interaction with mGluR5 [20]. To confirm
these findings and to identify the domain of PrPC mediating its interaction with mGluR5, we
studied a panel of transgenic mice expressing variants of PrPC bearing deletions in the flexi-
ble tail (FT) regions, designated ΔC, ΔCC, ΔF, ΔOR, and ΔHC [50–54] (S5E Fig). In each line
of mice, we immunoprecipitated PrPC from brain using POM1 antibody (specific informa-
tion and binding sites on PrPC are provided in S5F Fig and Table 1) and measured the co-
precipitation of mGluR5. Most FT-mutated PrPC variants showed an impaired capacity to
co-precipitate mGluR5, with deletions of residues 51–90 and 32–134 showing the most strik-
ing reduction (S5C Fig). Conversely, when we performed immunoprecipitations of mGluR5
followed by Western blotting for PrPC, we found that deletions spanning residues 111–134
affected the interaction most profoundly (Fig 5B).
We also analyzed the capacity of PrPC mutants to immunoprecipitate mGluR1. While all
examined FT mutations decreased the interaction of PrPC with mGluR1, deletions affecting
residues 51–90 showed the most significant reduction (S5D Fig). Immunoprecipitation of
mGluR1 revealed that PrPC deletions spanning residues 51–90 and 111–134 had the strongest
effect on its interaction with mGluR1 (Fig 5C). Finally, we observed that deletion of mGluR5
had no effect on co-precipitation of PrPC with mGluR1 (Fig 5C), indicating that mGluR1 and
mGluR5 interact with PrPC independently of each other.
neurodegeneration is rescued in the Grm5+/- and Grm5-/- HOCS. All scale bars: 500 μm. (B), (D) and (F): NeuN relative signal
intensity as percentage of control samples (Grm5+/+, NBH or POM1+recPrP); each dot corresponds to a pool of 7–10 cerebellar
slices or 4–6 hippocampal slices cultured in the same well; Data are presented as mean ± s.d.; One-way ANOVA followed by
Dunnett’s post-hoc test. *: P < 0.05, **: P < 0.01, ****: P < 0.0001.
https://doi.org/10.1371/journal.ppat.1006733.g004
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Fig 5. mGluR-interacting domains on PrPC. (A) Brain homogenate from wild-type (C57BL/6J) and Prnpo/o
mice was subjected to immunoprecipitation by POM1 followed by immunoblotting using polyclonal anti-mGluR5
(right) or anti-mGluR1 (left) and anti-PrPC antibodies. Control conditions (POM1 blocked by recombinant PrPC)
were run in parallel. The typical mGluR bands of 250kDa and 150kDa were detected in wild-type extract only
when immunoblotting with mGluR1 or mGluR5 antibody. Total brain extracts were in parallel subjected to
Western blot analysis to control for endogenous levels of mGluR5/1 and PrPC. (B-C) Mapping the mGluR5 and
mGluR1 interacting domains on PrPC. Brain homogenate from Tga20, Prnpo/o (ZH3) and amino proximal
deletion mutants of PrPC was subjected to immunoprecipitation by anti-mGluR5 (B) or anti-mGluR1 (C)
antibodies. For detection, we used polyclonal antibodies to mGluR5, mGluR1, and PrPC. Deletions
encompassing residues 111–134 of PrPC reduced its interaction with mGluR5, whereas deletions of residues
51–90 or 11–134 decreased the interaction with mGluR1. Total brain extracts (TEs) were subjected to Western
blot analysis to control for endogenous levels of mGluR5/1 and PrPC. Densitometric quantitation of the PrPC
signal was normalized over the ratio of PrP/Actin signal in TEs. N = 3–5; One-way ANOVA followed by Tukey’s
post-hoc test. Asterisk: P<0.05.
https://doi.org/10.1371/journal.ppat.1006733.g005
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These results suggest that the interaction domain between PrPC and mGluR5 resides at the
N-terminal region of PrPC and is larger than previously inferred, with residues 32–114 partici-
pating to the in vivo interaction. The interaction domain between PrPC and mGluR1 also
resides at the N-terminal region of PrPC and spans residues 51–90 and 111–134.
MPEP treatment reduces vacuole size and astrogliosis in prion-infected
mice
PrPSc deposition is accompanied by neurodegeneration, vacuole formation and activation of
microglia and astrocytes [55]. MPEP treatment did not affect the accumulation of PrPSc in
prion-infected mice and slices (S6A–S6C Fig), yet it reduced vacuole formation. Although the
numbers of vacuoles in control and MPEP treated groups were similar, vacuoles were smaller
in cerebella of MPEP-treated mice (Fig 6A and 6B). Astrogliosis, assessed by immunohis-
tochemistry for glial fibrillary acidic protein (GFAP), was prominent in terminally sick prion-
infected mice but not in NBH-inoculated mice. MPEP treatment reduced the astrogliosis in
the hippocampus of prion-infected mice (Fig 6C and 6D), but not in the cerebellar granule cell
layer (S6D Fig), as expected from the decreased expression of mGluR5 in the cerebellum of
older mice. These findings corroborate the interpretation that MPEP reduces prion toxicity
even if it does not affect prion load.
Prion-mimetic antibodies increase mGluR5 and PrPC translocation to
dendritic spines
Clusters of mGluR5 accumulate around excitatory synapses, but are also found at extra-synap-
tic sites (S7A Fig). Increased size of synaptic mGluR5s clusters is associated with toxic calcium
influx [21, 25, 56]. Therefore, we asked whether the prion-mimetic POM1 antibody altered the
clustering of mGluR5s. POM2 and POM3 antibodies were also used in parallel (for details
about POM antibodies and their epitopes, see Table 1). Specific information and binding sites
on PrPC for all antibodies are provided in (S5F Fig, Table 1) and materials and methods.
Exposure of live neurons to POM1, significantly increased the size of mGluR5s clusters
compared to POM2 or POM3 exposure (Fig 7A and 7B), however no change was observed
with the NMDA and AMPA receptor clusters (S7B–S7E Fig), suggesting formation of abnor-
mal, potentially deleterious mGluR5 signaling platforms [57]. Next, we examined the fluores-
cence of dendritic spines of neurons expressing an mGluR5-pHluorin fusion protein. Spines
in mGluR5-pHluorin transfected neurons indeed co-localize with post-synaptic marker
Homer, which is also a scaffolding protein for mGluR5 (S7F Fig). We observed increased accu-
mulation of mGluR5s in dendritic spines following exposure to POM1, but not to POM2 or
POM3 (Fig 7C and 7D).
Both mGluR5 and PrPC are enriched in postsynaptic densities [21]. In order to assess if the
changes in mGluR5s level in spines correlated with PrPC level in spines, we performed photo-
Table 1. Details of POM antibodies used in the current study.
Antibody Domain Epitope Epitope sequence on PrPC
POM1 GD β1-α1 loop, α1 and α3 138 − 147; 204/208/212
POM2 OR GQPHGGG/SW 57 − 64, 64 − 72, 72 − 80, 80 − 88
POM3 Hinge HNQWNK 95 − 100
POM1 binds to the globular domain (GD) of PrPC whereas POM2 binds to a degenerate epitope in the octapeptide repeat region (OR) and POM3 binds at
the center of the protein, designated as hinge region. Specific epitopes and the amino acids they span are depicted in the table.
https://doi.org/10.1371/journal.ppat.1006733.t001
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Fig 6. MPEP treatment reduces vacuole size and astrogliosis in prion-infected mice. (A-B) GFAP-stained
cerebellar sections from C57BL/6J mice injected i.c. with NBH or RML6 prions and treated with control or MPEP-
containing food respectively. Image areas as in figure (A) show spongiform vacuoles in the cerebellum. (B)
Mean ± SD of vacuole size was quantified as white area over the total area. Each graph shows a treatment group.
(C) Astrocyte proliferation was analyzed by immunohistochemistry with the GFAP antibody in paraffin-embedded
sections of hippocampal areas from C57BL/6J mice injected i.c. with NBH or RML6 prions and treated with
control or MPEP-containing food respectively. (D) Number of GFAP+ cells was quantified in the hippocampus.
Each graph corresponds to a treatment group. GFAP staining was markedly reduced in MPEP-treated mice
exposed to RML6 (3 log ID50 units). Graphs represent mean ± SD GFAP expression, quantified as the
percentage of the surface occupied by the GFAP staining over the total measured area. For all graphs,
quantification was based on 10 regions of interest per slice, 4 slices per mouse and 4 mice per treatment group.
****P<0.0001, **P<0.01; two-way ANOVA followed by Bonferroni’s post-hoc test.
https://doi.org/10.1371/journal.ppat.1006733.g006
Group-1 metabotropic glutamate receptors and prion toxicity
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006733 November 27, 2017 12 / 29
Fig 7. Exposure to Fab1-POM1 increases mGluR5 and PrPC translocation to dendritic spines. (A-B)
mGluR5 immunoreactivity following Fab1-POM1 administration to live neurons. Quantification of fluorescence
intensity (B) showed significantly increased size of mGluR5 clusters following exposure of live neurons to Fab1-
POM1 compared to Fab1-POM2 or Fab1-POM3. “ex vivo”: antibody administration to live neurons; “post
mortem”: administration to fixed neurons. The number of images analyzed was: 88 (control), 90 (POM1/live), 59
(POM2/live), 60 (POM3/live), and 30 (POM1/fixed; POM2/fixed; POM3). Results were pooled from three (ex
vivo) or two (post-mortem) independent experiments and distribution of the intensity is plotted (median, quartile,
10–90% distribution). The box plot shows median, quartile and 10–90% distribution and Mann-Whitney test was
performed to quantify the differences in distribution. Averaged mGluR5s intensity of clusters per experiment
(normalized to control) is also shown in top panel to represent experimental reproducibility (Controls = 1; POM1
(live) = 1.36, 1.19, 1.16; POM2 (live) = 1.17, 1.13, 1.01, POM3 (live) = 1.10, 1.11, 0.89; POM1 (fixed) = 1.14,
0.89; POM2 (fixed) = 1.21, 1.01; POM3 (fixed) = 1.30, 0.93). (C-D) Increased mGluR5s immunoreactivity in
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activated localization microscopy (PALM) on neurons expressing a PrPC tagged with dendra2
fusion protein [58] (Fig 7E). PALM images were obtained from single-molecule detection with
a pointing accuracy of 20 nm [58]. The PrPC-Dendra fluorescence patterns showed both clus-
tered and diffused staining (Fig 7E, control); we observed an increased enrichment within den-
dritic spines following POM1 but not POM1+2 exposure (Fig 7E and 7F). Furthermore,
exposure to Fab1-POM2, which was previously found to protect against POM1 toxicity [41],
induced a small but significant reduction in PrPC enrichment within dendritic spines. There-
fore, Fab1-POM1 and Fab1-POM2 may exert opposite effects on the topology and size of
mGluR5 clusters, with POM1 inducing abnormal accumulation and translocation to dendritic
spines.
Discussion
Prion toxicity is ultimately mediated by unfolded-protein responses [3, 59], yet it is unclear
how these are triggered by PrPSc which is primarily extracellular. The group-I metabotropic
glutamate receptors mGluR5 and mGluR1, G protein-coupled receptors that interact with
PrPC [19, 21, 25], may represent one such link. We found that mGluR5 and mGluR1 inhibitors
prevented neurodegeneration in prion-infected organotypic slice cultures and protected
against prion-mimetic globular-domain ligands [41]. Inhibition of group-I mGluRs may
reduce glutamatergic signaling and calcium overload in prion-infected cells [60], similarly to
models of Alzheimer’s disease [21, 25].
PrPC associates with group-I mGluRs [47] and modulates the signaling activity of mGluR5
[20]. If prion toxicity depends on the direct interaction of PrPC to group-I mGluRs, it may
modify the subcellular distribution of mGluR5. Indeed, prion-mimetic antibodies selectively
increased clustering of mGluR5 (but not of AMPA and NMDA receptors) in dendritic spine
heads, potentially sensitizing them to synaptic glutamate. Prion-mimetic antibodies also
increased the level of PrPC in spines, reinforcing the notion that mGluR5 and PrPC are part of
the same complex whose accumulation at excitatory synapses instigates neurotoxicity in prion
diseases. The impact of POM1 on mGluR5 enrichment within dendritic spines is modest, pos-
sibly because only a small fraction of mGluR5 is associated with PrPC. Increased cell surface
clustering may also slow down endocytosis, thereby increasing the amount of functional
mGluR5s [21, 23, 61]. Thus, mGluR5 clustering at synapses may amplify responses to gluta-
mate, thereby exaggerating Ca2+ influx and leading to spine loss, a primary event in prion dis-
eases [62]. The POM2 antibody [45] against the Flexible Tail (FT) of PrPC is neuroprotective
in vivo and in vitro. Since both POM2 and mGluR5 bind to the N-terminus of PrPC, binding
of mGluR5 to PrPC may facilitate its activation whereas POM2 may compete for PrPC binding
(Fig 8).
dendritic spines following Fab1-POM1 exposure. (C) Representative images showing the expression of
mGluR5-pHluorin in untreated and Fab1-POM1-treated neurons (1 μg, 1 h). (D) Fluorescence ratio (spine/shaft)
emphasizing the increase in mGluR5-pHluorin level in spines following exposure to Fab1-POM1, but not to Fab1-
POM2 or a mixture of Fab1-POM1 and Fab1-POM2. Number of spines analyzed (n): 821 (control), 894 (Fab1-
POM1), 739 (Fab1-POM2), 669 (Fab1-POM1+2). The box plot shows median, quartile and 10–90% distribution
and Mann-Whitney test was performed. Averaged (normalized to control) spine enrichment value per experiment
is also shown (top panel) to represent experimental reproducibility (Controls = 1; POM1 = 1.18, 1.10, 1.03;
POM2 = 1.03, 0.96, 0.98; POM1+2 = 1.00, 0.97; 1.07). (E-F) Spine enrichment of PrPC following exposure to
Fab1-POM1. (E) Single-molecule detection of PrPC-Dendra by photoactivated localization microscopy (PALM)
on dendritic spines and shafts for untreated or following antibody treatment (1μg, 1h). (F) Ratio of molecular
density in spine versus dendritic shaft emphasizing spine-enrichment of PrPC-Dendra following exposure to
Fab1-POM1 but not to other antibodies. Number of spines analyzed (n): 318 (control), 328 (POM1), 364 (POM2),
331 (POM1+2), 416 (POM3). All plots show median, quartile and 10–90% range. Mann-Whitney test; *p<0.05,
***p<0.001, ns = non-significant. Scale bars: 2μm.
https://doi.org/10.1371/journal.ppat.1006733.g007
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Although mGluR5 inhibition delayed neurological deterioration, survival was only mod-
estly (though significantly) improved. These findings support the concept that mGluR5 inhibi-
tion alleviates the symptoms of the disease whereas prion replication progresses unabated.
Eventually, the prion load may exert neurotoxicity through mGluR5-independent mechanisms
including mGluR1 activation. Not all neurons express mGluR5 [63, 64]; neurons essential for
survival may be mGluR5-negative and possibly mGluR1-positive.
Upregulation of mGluR5 can go along with glial activation [56, 65, 66]. We observed
reduced GFAP immunoreactivity in hippocampi of MPEP-treated animals (Fig 6C). Con-
versely, MPEP was unable to suppress glial activation in adult cerebella (S6D Fig) where
mGluR5 expression is low, suggesting that dampened neuroinflammation was beneficial.
Genetic ablation of Grm5 was protective against the toxicity of prion-mimetic antibodies
and prion infections in organotypic slices. This effect was haploinsufficient, as hemizygous
Grm5+/- slices were also protected. Surprisingly, a previous report [46] and this study show
that Grm5 ablation does not ameliorate the clinical manifestation of scrapie in vivo. This dis-
crepancy is most likely due to the conspicuous mGluR1 upregulation in Grm5-/- and Grm5+/-
mice.
Co-immunoprecipitations from transgenic mice expressing PrPC with amino-proximal
deletions [50–54] showed that both mGluR1 and mGluR5 independently interact with the N-
proximal flexible tail of PrPC. However, the boundaries of the interacting domain differ, with
PrPC residues 32–134 (with residues 51–90 (ΔOR) and 111–134 (ΔHC) acting as important
interaction sub-regions) mediating the interaction with mGluR5. The interaction domain
appears to extend over the previously reported borders [31]. The interaction domain between
Fig 8. Model of the interactions between mGluR5, PrPC, and anti-PrP antibodies. (A) In untreated
neurons, mGluR5-PrPC complexes are distributed within and outside spines. Upon exposure to prion-mimetic
antibodies (B), mGluR5 translocates to the spine, where it may enhance neurotoxicity by contributing to a
Ca2+ overload. (C) Exposure to POM2, in contrast, engages the N-terminal “flexible tail” of PrPC, thereby
making it unavailable to mGluR5. Consequently, mGluR5-PrPC (and possibly also mGluR1-PrPC) complexes
do not translocate to spines. As a result, POM2 affords functional neuroprotection similarly to mGluR5
antagonists. (D) We speculate that prion infection may trigger topological rearrangements similar to those
observed after POM1 exposure.
https://doi.org/10.1371/journal.ppat.1006733.g008
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PrPC and mGluR1 also resides at the N-terminal region of PrPC and spans residues 51–90
(ΔOR region) and 111–134 (ΔHC region).
Although both Grm5 genetic deletion and mGluR5 pharmacological inhibition (MPEP) did
not prevent prion disease, MPEP significantly improved locomotor abilities until the later
stage of disease, decreased the size of spongiform vacuoles, and reduced the extent of hippo-
campal astrogliosis. These observations are aligned with reports of abnormal expression of
group-I mGluRs and mGluR1 signaling in Creutzfeldt-Jakob disease and bovine spongiform
encephalopathy [10, 67]. Additional mGluRs may also play a role, and a genome-wide associa-
tion study identified an mGluR8 variant as a marker for sCJD risk outside the PRNP locus
[68].
The above data suggest that group-I mGluRs inhibition may attenuate dysfunctions associ-
ated with prion diseases, for which there are no disease-modifying therapies. It is unsurprising
that mGluR5 antagonists have only a moderate effect on survival, since this therapeutic modal-
ity is likely to affect downstream consequences of prion toxicity rather than quenching prion
propagation. Because of their orthogonal mode of action, these antagonists may represent
ideal compounds for combination therapy with compounds inhibiting prion replication.
Because they are well-tolerated and have high bioavailability and blood-brain-barrier penetra-
tion [15, 69, 70], mGluR5 antagonists may be useful for enhancing the quality of life of prion
patients—a legitimate and important aim even if the overall life expectancy may not be dra-
matically improved.
Materials and methods
Study design
The purpose of this study was to evaluate the therapeutic potential of group I metabotropic
glutamate receptor (mGluR1, mGluR5) inhibition in ex vivo and in vivo models of prion dis-
ease. We selected highly specific and well-studied pharmacological inhibitors of mGluR1 and
mGluR5, YM202074 and MPEP and AGQ056 respectively, with known specificity and effi-
ciency. To ensure availability of the inhibitors to the brain of prion-infected mice thorough
pharmacokinetic and pharmacodynamic analyses were performed. We further extended our
study to transgenic mice, knock out for the glutamate receptors being studied. For slice experi-
ments, treatments were randomly assigned to individual wells. For mouse experiments, treat-
ments were randomly assigned to age- and sex-matched mice; experimenters were blinded to
experimental group while performing the animal experiments. For experiments with trans-
genic mice, similar number of heterozygotes and wild-type littermates were included as con-
trols. Mice were sacrificed at the terminal stage of the disease. For analysis, random numbers
were assigned to each subject or experimental group.
Ethics statement
All animal procedures were approved by the local Ethical Committee (Animal Experimentation
Committee of the Canton of Zurich, permit 200/2007; 41/2012; 90/2013) in accordance with
the Swiss federal, Ethical Principles and Guidelines for Experimenting on animals (3rd edition,
2005). All efforts were made to minimize the suffering and the number of animals used.
Mice
C57BL/6J wild-type mice were purchased from Jackson laboratories. Male mice were selected
because they do not have estrous cycles that can complicate pharmacology. Prnpo/o and
Prnpo/o;tga20+/+ (tga20), were on a mixed 129Sv/BL6 background [71, 72]. Transgenic mice
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expressing mutated PrPC were utilized for immunoprecipitation experiments. The production
and relevance to disease phenotype of the Tg mice expressing N-terminal deletion mutants of
PrPC (termed ΔC, ΔCC, ΔF, ΔOR, and ΔHC) have been previously reported [50–54]. Grm5+/-
embryos [73, 74] were acquired from Dr. Gasparini and were revitalized at the transgenics
facility of the University Hospital of Zurich. Grm5 null mice were derived from breeding of
these mice.
Pharmacological treatments
2-Methyl-6-(phenylethynyl)-pyridine (MPEP) [36] chronic treatment was initiated at the time
of prion inoculation. A dose of 30 mg of MPEP/kg of body weight was selected [75]. The drug
was incorporated into chow to achieve voluntary consumption and constant drug administra-
tion. Control, untreated groups received the same type of food lacking the drug. For this study,
mice between 2 and 4 months of age at the time of prion inoculation/beginning of MPEP treat-
ment were utilized.
To determine PK values in mice fed with food pellets containing MPEP (250mg/kg; Pro-
vimi Kliba SA, Rinaustrasse 380, CH-4303 Kaiseraugst), 10 C57BL/6J mice were fed MPEP-
food pellets for 15 days and sacrificed to measure the blood/brain ratio of MPEP. Based on an
average intake of 3 gram food pellets per day and a body weight of approximately 25 g, a dose
of 30mg/kg/day was established. The MPEP concentration was determined by liquid chroma-
tography separation followed by mass spectrometry (LC-MS). Control mice (a total of 8
C57BL/6J mice) received normal food. Mice were sacrificed at two different time points, corre-
sponding to the active and the inactive phase of the mice across the circadian circle and expo-
sures of MPEP in blood and brain were measured.
Organotypic slice culture preparation
Organotypic cerebellar cultured slices, 350 μm thick, were prepared from 9–12 day-old pups
according to a previously published protocol [32]. Organotypic hippocampal cultured slices,
350 μm thick, were prepared from 4–6 day-old pups according to a previously published pro-
tocol [33]. Cultures were kept in a standard cell incubator (37˚C, 5% CO2, 95% humidity) and
the culture medium was changed three times per week.
Prion inoculation and GDLs treatment
Inoculations were performed with either infectious brain lysate (RML6) or non-infectious
brain homogenate (NBH). Slices were inoculated (as free-floating sections for 1 h at 4˚C) with
100μg brain homogenate per 10 slices. After washing in GBSSK, they were cultured on a 6-well
Millicell-CM Biopore PTFE membrane insert (Millipore) according to previously published
protocol [60]. Drug-treated tga20 slices were maintained until 45 dpi, fixed and analyzed by
NeuN morphometry (analySIS vc5.0 software). Neurotoxicity was defined as significant
NeuN+ neuronal layer loss over NBH treatment. Slices prepared from GRM5-/-, GRM5+/- and
GRM5+/+ littermates were maintained until 60 dpi, fixed and analyzed by NeuN morphometry
(analySIS vc5.0 software). Neurotoxicity was defined as significant NeuN+ neuronal layer loss
over NBH treatment.
For globular domain ligand (GDL) treatment, toxicity in slices was induced by exposure
to ligands, toxic anti- PrPC antibodies targeting the globular domain, such as single chain
scPOM1 mini-antibody, after a 14-day recovery period; allowing the initial gliosis induced by
tissue preparation to subside, according to previously published protocol [41]. tga20 COCS
were exposed to scPOM1 (200 nM, 8 dpe), or to control treatment (200 nM scPOM1/210nM
recPrP, 8 dpe), immunostained for the neuronal marker NeuN and counterstained with DAPI.
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Slices were imaged and analysed as previously described. Antibody treatment was randomly
assigned to individual wells.
Pharmacological treatment of slices
Treatment with the specific inhibitors 2-Methyl-6-(phenylethynyl)-pyridine (MPEP) [36],
AFQ056 (Mavoglurant) [37] or N-cyclohexyl-6-N-methylthiazolo[3,2-a]benzimidazole-2-car-
boxamide (YM202074) [35] was initiated at the time of GDL addition (14dpe) for the GDL
toxicity model (treated slices were maintained until 28 dpe for POM1 treatment and until
22dpe for scPOM1 treatment) [41] and at 21 days post-inoculation (dpi) for prion-infected
slices, when PrPSc accumulation was already discernible [32]. Drug treatments were re-added
at every media change [36]. Post-treatment slices were fixed in 4% paraformaldehyde (PFA),
immunostained for the neuronal marker NeuN and counterstained with DAPI. Slices were
imaged at 4x magnification on a fluorescence microscope (BX-61, Olympus) analyzed by
NeuN morphometry (analySIS vc5.0 software). Neuroprotection was defined as significant
neuronal layer rescue over toxic-antibody treated, non-drug treated slices.
Prion inoculations
Inoculum of the RML6 strain of mouse-adapted scrapie prion was prepared from pooled 10%
w/v brain homogenates of RML6 terminally sick CD1 mice. C57BL/6J mice were inoculated
with serial dilutions (10−3 and 10−5) of the RML6 inoculum. C57BL/6J mice were injected
intracerebrally (i.c.) with 30μl of brain homogenate prepared in a solution of PBS/5% BSA,
containing 3log LD50 units or 5log LD50 units of the RML6 strain. Control mice received 30μl
of NBH derived from healthy CD1 mice. Scrapie was diagnosed according to clinical criteria
(ataxia, kyphosis, priapism, and hind leg paresis). Mice were sacrificed on the day of onset of
terminal clinical signs of scrapie. The operator was blinded to drug treatment.
Rotarod tests
The rotarod test was used to assess motor coordination and endurance at defined timepoints
after prion inoculations. A rotarod machine (Ugo Basile) with five cylinders (3cm diameter)
separated by dividers (25cm diameter) in five lanes, each 57mm wide, was utilized. Before the
training sessions, the mice were habituated to stay on the rotating rod (4 rpm lowest speed)
for 3 sessions lasting 1–2 minutes each and separated by 10 minute intervals. The test phase
started 30 minutes after the last habituation session and consisted of 3 trials separated by 15
minute inter-trial intervals. For each test session the mouse was placed on a rotating rod,
which accelerated from 5 to 40 rpm. Each test session lasted a maximum of 5min. Latency to
fall was assessed when the mouse was no longer capable of riding on the accelerating rod and
slipped from the drum. Test sessions were always performed at the same time of the day, mice
were tested in a randomized manner and the operator was blind to drug treatment.
Brain homogenization and immunoprecipitation
Adult Prnpo/o, tga20+/+ (tga20), and C57BL/6J mice were euthanized and their brains were dis-
sected. Brain samples were snap frozen in liquid nitrogen. Samples were subsequently homog-
enized in ice cold Lysis Buffer (1% Igepal (NP-40) in 1x PBS, pH 7.4) supplemented with
protease (EDTA-free) and phosphatase inhibitor cocktail mix (Roche). Protein concentration
was determined using the bicinchoninic acid assay (Pierce). Following immunoprecipitation
of PrPC with a specific anti-PrP monoclonal antibody (POM1 or POM2) and addition of
Dynabeads M-280 Sheep anti-mouse (#311201D, Thermo Fischer Scientific), samples were
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prepared in loading buffer (NuPAGE, Invitrogen) and incubated at 37˚C for 30 min. For the
immunoprecipitation data shown in S4B and S4C Fig, the samples were incubated at 95˚C for
5 min; this resulted in disruption of dimers of mGluR5. However this did not have any effect
on the immunoprecipitated fractions. The samples were migrated on 4–12% NuPage gels and
transfered onto the PVDF membrane. For reverse immunoprecipitation experiments, the
subsequent experimental set-up was used. Following immunoprecipitation of mGluR1 or
mGluR5 with a specific anti-mGluR1/5 polyclonal antibody (Cell Signalling Technology
#12551 or #55920 respectively) and addition of Dynabeads Protein G (#10003D, Thermo
Fisher Scientific), samples were prepared in loading buffer (NuPAGE, Invitrogen) and incu-
bated at 37˚C for 10–30 min [76]. The samples were migrated on 4–12% NuPage gels and
transferred onto the PVDF membrane.
Antibodies and chemicals
All compounds were purchased from Sigma-Aldrich unless otherwise stated. Monoclonal anti
PrP antibody POM1 (1:5000) was generated as described previously [45]. Anti-mGluRs anti-
bodies against representative receptors of each group, targeting the N-terminal domain were
utilized: anti-mGluR5 #ab53090 (Abcam) or AB5675 (Millipore), anti-mGluR1 [EPR13540]
(ab183712) (Abcam), anti-mGluR2+3 #ab6438 (Abcam) and anti-mGluR6 #AGC-026 (Alo-
mone labs). Secondary antibodies were horseradish peroxidase (HRP)- conjugated rabbit
anti–mouse IgG1 (1:10,000, Zymed) and goat anti–rabbit IgG1 (1:10,000, Zymed). Blots were
developed using SuperSignal West Pico chemiluminescent substrate (Pierce) and visualized
using the VersaDoc system (model 3000, Bio-Rad). Rocky Mountain Laboratory strain (RML;
passage #6) prions (RML6) were amplified in CD1 mice by intracerebral inoculation into the
lateral forebrain of 30 μl of 1% (wt/vol) brain homogenate. The mGluR5 antagonists MPEP
and AFQ056 were kindly provided by Novartis. The mGluR1 antagonist YM202074 was pur-
chased from Tocris Bioscience (Ellisville, USA).
Immunohistochemistry and NeuN morphometry
Immunohistochemistry of fixed organotypic slices and subsequent NeuN morphometric anal-
ysis was performed according to previously published protocols [41, 60].
Histology and immunohistochemistry
Stainings were performed on sections from brain tissues fixed in formalin and treated with
concentrated formic acid to inactivate prions. Partially protease-resistant prion protein depos-
its, astrogliosis and microglia deposition were visualized by staining brain sections with the
SAF84 antibody (1:200, SPI bio), GFAP (1:1000, Millipore) and IBA1 (1:2500, WAKO) respec-
tively on a NexES immunohistochemistry robot (Ventana instruments) using an IVIEW DAB
Detection Kit (Ventana), after preceding incubation with protease 1 (Ventana). Images of
DAB stained sections were acquired using the NanoZoomer scanner (Hamamatsu Photonics)
and NanoZoomer digital pathology software (NDPview; Hamamatsu Photonics). Quantifica-
tions of IBA1, GFAP staining and vacuoles in mouse sections were performed on acquired
images; regions of interest were drawn on a Digital Image Hub (Leica Biosystems) and ana-
lyzed as previously described [77].
Primary neuronal culture
Hippocampal neurons were prepared from embryonic day 18 (E18) C57/BL6 mice (Janvier
Labs, France). Freshly dissociated (trypsin) cells were plated (80,000 cells per 18 mm coverslip
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per ml) in neuronal attachment media consisting of 10% horse serum, 1 mM sodium pyruvate,
and 2 mM glutamine in MEM for 3h. The attachment medium was replaced and cells were
maintained in serum-free neurobasal medium supplemented with B27 (1X) and glutamine (2
mM). 300 μl of fresh medium was added once a week.
Plasmids and transfection
mGluR5-pHluorin construct [78]was generated and kindly provided by Lili Wang and Chris-
tian Specht. Dendra2 was inserted between residues Q222 and A223 of mouse prion protein.
GluN2A-GFP was kindly provided by Andrea Yao and Pierre Paoletti. Transfection was per-
formed on DIV 17–18 neurons using Lipofectamine as described recently [58]. Transfection
medium (TM) was composed of 1 mM sodium pyruvate and 2 mM glutamine in nerobasal
medium (Invitrogen). 0.5 μg of plasmid and 2 μl of lipofectamine- 2000 reagent were used for
each coverslip. All in vitro experiments were performed on mature neurons (DIV 21–24)
Immunocytochemistry and image analysis
Immunocytochemistry of mGluR5 (rabbit polyclonal, Millipore, AB5675, 1:200 dilution) or
GluR2-AMPA receptor (rabbit polyclonal, Synaptic System, 182103, 1:400 dilution) was per-
formed following methanol fixation / permeabilization (10 min at -20˚C; methanol pre-stored
at -20˚). Image thresholding using wavelet decomposition to identify fluorescent clusters
(mGluR5 and GluR2-AMPA immunoreactivity or GluN2-GFP fluorescence) has been
described in previous studies [25, 58]. Size of clusters denotes the total fluorescence intensity
of the given cluster. Images were acquired using Leica Inverted Spinning Disk microscope
(DM5000B, Coolsnap HQ2 camera, Cobolt lasers) using 100X objective (field of view = 1392 x
1040 pixels) and a pixel size of 60.5nm. For estimation of mGluR5 fluorescence within den-
dritic spines, ratio of fluorescence within a circular region of fixed size (6 pixel) on spine head
to the shaft below was measured using ImageJ program.
Photoactivated localization microscopy (PALM) and analysis
PALM was performed on live neurons expressing PrPc-Dendra2 and the microscope setup
and lasers used have been recently described in detail [58]. Unconverted Dendra2 has excita-
tion and emission maxima at 490 and 507 nm (green range) while converted Dendra2 protein
has excitation and emission maxima at 553 and 573 nm (red range). First, all signal in red
channel was photo-bleached to allow detection of single molecule events arising due to the
switching of Dendra2 from green to red channel. Single molecule events of Dendra2 were
imaged using laser 561 nm (0.5kW, used at 300-400mW) while activating with 405 nm laser
(100 mW power, used at 2–5 mW). PrPc-Dendra2 was imaged for 5000–6000 frames. Single
molecule detections using in-house software has been used and described in previous publica-
tions [58]. Density of detections (number/area) of single-molecule on spine head was divided
by density of detections over a dendritic shaft to obtain spine enrichment of PrPC-Dendra2.
Dendrites were not filled with any additional post-synaptic marker. Mature neurons (DIV
21–24) were transfected with mGluR5-SuperEcliptic pHluorin. The pHluorin-tag allows the
visualization of only cell-surface mGluR5s and the neuronal membrane, which is then visually
recognizable. We have recently used this plasmid to compute the diffusion dynamics of
mGluR5s within dendritic spines [78] In this study, we quantified the spines enrichment of all
recognizable spines; considering that visually recognizable spines in mGluR5-pHluorin trans-
fected neurons indeed colocalize with post-synaptic marker, Homer (which is also the scaffold
of mGluR5).
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Statistical analysis
Detailed image analysis information is provided in the figure legends. For NeuN morphomet-
ric analysis (Figs 1, 3, 4, S1 and S3), NeuN values are normalized to the median NeuN value of
the NBH or Ctrl samples respectively. Two-way ANOVA, followed by Bonferroni correction
or Log-rank (Mantel-Cox) test was performed in Fig 2, to measure statistical differences
between groups. One-way ANOVA followed by Dunnet’s post-hoc test was performed to mea-
sure statistical differences between groups. Two-way ANOVA, followed by Bonferroni correc-
tion was performed for Fig 4G. For Western Blot quantification in S4 Fig, mGluR1/actin ratios
were normalized to the mean Grm5+/+ sample mGluR1/actin ratio in each timepoint (45days,
90days, 180days). One-way ANOVA followed by Tukey’s post-hoc test was performed to mea-
sure the statistical differences between the groups. For IP quantification in Figs 5 and S5, den-
sitometric quantitation of PrP signal or mGluR1/5 respectively from the immunoprecipitation
was normalized over the ration of PrP/Actin or mGluR1/Actin or mGluR5/Actin signal in TEs
respectively. One-way ANOVA followed by Tukey’s post-hoc test was performed to measure
the statistical differences between the groups. For immunohistochemistry analysis in Figs 6
and S6, number of GFAP+ cells or vacuoles was quantified in different brain regions. GFAP
expression, quantified as the percentage of the “brown” surface occupied by the GFAP staining
over the total measured area. Vacuolation, quantified as the percentage of “white” surface
occupied over the total measured area. Two-way ANOVA, followed by Bonferroni correction
was performed to measure statistical differences between groups. Non-parametric Mann-
Whitney test was performed in Fig 7 to measure the statistical differences between the distribu-
tions. GraphPad Prism (GraphPad Software) was chosen for the statistical analysis.
Supporting information
S1 Fig. Treatment with MPEP or YM202074 rescues prion (RML6) toxicity in wild type
cerebellar organotypic cultured slices (COCS). Assessment of mGluR5 expression levels in
10-day old samples (COCS and brain homogenates). (A-B) Treatment with a mGluR5 or
mGluR1 inhibitor (MPEP or YM202074, respectively) rescued neurodegeneration in wild type
(C57BL/6J) RML6-treated COCS. (A) Fluorescence micrographs of wild type (C57BL/6J)
COCS showing degeneration of the cerebellar granular layer (CGL) induced by RML6 infec-
tion, that is significantly ameliorated by addition of MPEP or YM202074. (B) NeuN mor-
phometry of wild type (C57BL/6J) COCS exposed to RML6 or NBH, and treated with MPEP
or YM202074 (dpi: 21–60 days post inoculation). (C) Fluorescence micrographs of tga20
COCS, showing no toxicity on slices treated with high concentrations of MPEP. (D) Fluores-
cent micrographs of tga20 COCS, infected with RML6 and treated with high concentrations
(3-10 μM) of MPEP. High concentrations of MPEP were not protective against prion infec-
tion. (E) mGluR5 localization in tga20 COCS imaged by confocal microscopy. The mGluR5
receptor (green) was highly expressed in neuronal and non-neuronal cells in cerebellar slices.
Neurons were stained with pAb against NeuN (red); nuclei were counterstained with DAPI
(blue). For (B) panel: Scatter dot plots represent NeuN relative signal intensity as percentage
of NBH samples; each dot corresponds to a pool of 5–8 cerebellar slices cultured in the same
well; Data are presented as mean ± s.d.; One-way ANOVA followed by Dunnett’s post-hoc
test. For (A), (C) and (D) panels: Scale bar is 500 μm. For (E) panel: Scale bar is 50μm.
(TIF)
S2 Fig. MPEP is effectively delivered to the brain, does not induce changes in food and
water consumption and rotarod performance of non-infectious brain homogenate (NBH)
inoculated mice. (A) Control mice injected with NBH and treated with MPEP exhibited stable
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rotarod performance during the entire test period, up to 23 weeks post-injection. Each dot cor-
responds to a mouse. Two-way ANOVA per each time point revealed no significant difference
in the latency to fall of NBH-injected, MPEP treated mice during the course of the study. (B)
No significant changes in average food and water consumption were observed between control
and treatment (MPEP) groups during the experiment. Experiments were run in parallel. Data
are presented as mean ± s.d.; One-way ANOVA followed by Dunnet’s post-hoc test (C) Mice
treated with control and MPEP food were sacrificed at time points corresponding to the active
and the inactive phase across the circadian circle, to determine the exposure of the brain to
MPEP. The results indicated the average brain to plasma ratio (Kp) for the MPEP concentra-
tion to be around 1; suggesting that the current treatment scheme allows good exposure of the
brain to MPEP.
(TIF)
S3 Fig. Treatment with MPEP and/or YM202074, but not L-AP4 and CPPG rescues GDL
toxicity in wild type cerebellar organotypic cultured slices (COCS). (A-B) Treatment with
the mGluR5 inhibitor (MPEP) and/ or the mGluR1 inhibitor (YM202074) rescued neurode-
generation in WT (C57BL/6J) scPOM1-treated COCS. (A) Fluorescence micrographs of WT
COCS showing ablation of the cerebellar granular layer (CGL) induced by scPOM1 treatment,
that is ameliorated by addition of MPEP, YM202074 or both inhibitors at low concentrations
(C = 100-200nM). (B) Graphical representation of NeuN morphometry of WT (C57BL/6J)
COCS exposed to scPOM1 or control (scPOM1 blocked with recPrP) and treated with MPEP,
YM202074, or both. Treatment at 14–22 days post POM1 exposure (dpe). (C-D) Treatment
with a selective agonist of group III (L-AP4, 500nM) and a potent antagonist of group II-III
(CPPG, 200nM) metabotropic glutamate receptors did not rescue neurodegeneration in tga20
scPOM1-treated COCS. (D) NeuN morphometry of tga20 slices exposed to scPOM1 or con-
trol (scPOM1 blocked with recPrP) and treated with L-AP4 or CPPG at 14–22 dpe. (E) Fluo-
rescence micrographs of tga20 COCS showing ablation of the cerebellar granular layer (CGL)
induced by scPOM1 and its amelioration by MPEP. (F) NeuN morphometry of tga20 COCS
exposed to scPOM1 or control (scPOM1 blocked with recPrP) and treated with MPEP at 14–
22 dpe. For panels (B), (D) and (F): Scatter dot plots represent NeuN relative signal intensity
as percentage of scPOM1+recPrP control samples; each dot corresponds to a pool of 7–10 cer-
ebellar slices in the same well; Data are presented as mean ± s.d.; One-way ANOVA followed
by Dunnett’s post-hoc test; : P < 0.001. For (A), (C) and (E) panels: Scale bar is 500μm.
(TIF)
S4 Fig. Grm5 deletion induces compensatory mGluR1 upregulation and does not prolong
survival of prion-infected mice. (A) Survival of Grm5+/+, Grm5+/- and Grm5-/- mice inocu-
lated i.c. with 5 log LD50 units of RML6, n = 4–6 males per group. Each dot corresponds to a
mouse. Two-way ANOVA per each time point revealed a non-significant difference between
Grm5+/+, Grm5+/- and Grm5-/- groups. (B) Total brain extracts from mice inoculated with
NBH and received control or MPEP food, as well as control WT brain lysates, were subjected
to western blot analysis to evaluate whether MPEP treatment changes the expression of
mGluR1 receptor. No differences were observed in the mGluR1 expression levels between the
samples. (C) Cerebellar extracts from Grm5-/-, Grm5+/- and Grm5+/+ mice, collected at postna-
tal day 10 (comparable with the organotypic slices), were subjected to western blot analysis to
control for endogenous levels of mGluR5. mGluR5 expression in the cerebellum was similar to
that of hippocampus and cortex. (D) Epistatic interactions between mGluR1 and mGluR5
receptors. Brain extracts from cerebellum, cortex and hippocampus of 45, 90 and 180-day old
Grm5-/-, Grm5+/- and Grm5+/+ mice were subjected to western blot analysis for mGluR1 and
mGluR5. With increasing age mGluR5 expression decreased in all brain regions. Expression of
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mGluR1 remained stable in all genotypes. However, increased mGluR1 expression was
detected in samples from Grm5-/- mice. In hippocampi, we observed higher expression of
mGluR1 in samples from Grm5-/- mice at 90 and 180 days of age than in heterozygous and
wild-type littermates (bottom right panel). In the cortex, increased expression of mGluR1 in
samples from Grm5-/- mice were observed at the earliest timepoint (45 days). In cerebellum,
we observed increased expression of mGluR1 in Grm5-/- mice at the intermediate timepoint
(90 day). Expression levels of mGluR1 were similar in Grm5-/- and Grm5+/+ samples at all ages
except in 180-day old hippocampal samples (lower panel, lanes 7 and 8). Graph bars represent
normalized mGluR1 signal; N = 3–5; One-way ANOVA followed by Tukey’s post-hoc test; n:
P<0.05.
(TIF)
S5 Fig. PrPC specifically interacts with mGluR1/5 and not with group II and III mGluRs.
(A) Total brain extacts from wild-type (C57BL/6J), Tga20 and Prnpo/o mice was subjected
to western blot analysis for the endogenous levels of mGluR5 and mGluR1. Expression of
mGlur5/1 was similar in all the three mice model systems. (B) Brain homogenate from wild-
type (C57BL/6J) and Prnpo/o mice was subjected to immunoprecipitation by POM1 followed
by immunoblotting using polyclonal anti-mGluR2/3 and anti-mGluR6, or anti-PrPC antibod-
ies. mGluR2/3 and mGluR6 did not coprecipitate with PrPC. Total brain extracts were in paral-
lel subjected to Western blot analysis to control for endogenous levels of mGluR2/3 or 6 and
PrPC. (C-D) Mapping the mGluR5 and mGluR1 interacting domains on PrPC. Brain homoge-
nate from wild-type, Prnpo/o (ZH3) and amino proximal deletion mutants of PrPC was sub-
jected to immunoprecipitation by POM1, followed by immunoblotting using polyclonal anti-
mGluR5 (C) or anti-mGluR1 (D) and anti-PrPC antibodies. Deletions extending from residues
51–90 and 32–134, corresponding to the OR (octapeptide repeat region) and the flexible tail of
PrPC, reduced the interaction with mGluR5, whereas deletions extending from residues 51 to
90, corresponding to the OR region of PrPC, decreased the interaction with mGluR1. Total
brain extracts (TEs) were subjected to Western blot analysis to control for endogenous levels
of mGluR5/1 and PrPC. Densitometric quantitation of mGluR1 or mGluR5 signal from the
immunoprecipitation was normalized over the ration of Grm/Actin signal in TEs. Graphs rep-
resents mGluR1 or mGluR5 relative signal intensity; N = 3–5; One-way ANOVA followed by
Tukey’s post-hoc test; n: P<0.05. : band corresponding to recombinant PrP. (E) Schematic
representation of PrPC deletion mutants. Toxic POM1 antibody binds to a1-a3 helixes (resi-
dues 138–147; 204/208/212), innocuous POM2 antibody binds to octapeptide repeat (OR)
region (residues 57–88), whereas POM3 antibody binds to residues 95–100 on PrPC.
(TIF)
S6 Fig. PrPSc accumulation in prion-infected slices or in the brain of prion-infected mice is
not altered by MPEP treatment. (A) Total PrP and PrPSc levels (detected by addition of pro-
teinase K (PK)) in homogenates from different brain regions (hippocampus and cerebellum)
of terminal C57BL/6J mice injected i.c. with NBH or RML6 prions and treated with control or
MPEP-containing food respectively. Control NBH and RML6 samples, with or without addi-
tion of PK were run in parallel. (B) Representative images of SAF84-stained cerebellar and hip-
pocampal sections from C57BL/6J mice injected i.c. with NBH or RML6 prions and treated
with control or MPEP-containing food respectively. The levels of PrPSc (detected by SAF84
immunohistochemistry) are similar in brain sections from prion-infected mice treated with
control or MPEP-containing food. (C) Total PrP and PrPSc levels (detected by addition of pro-
teinase K (PK)) in homogenates from RML6 infected cerebellar slices prepared from tga20 or
PrPo/o mice. Cerebellar slices infected with RML6 prions were also treated with MPEP accord-
ing to the previously described protocol. Control NBH samples, with or without addition of
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PK were run in parallel. (D) Astrocyte proliferation was analyzed by immunohistochemistry
with the GFAP antibody on cerebellar sections from C57BL/6Jmice injected i.c. with NBH or
RML6 prions and treated with control or MPEP-containing food respectively. Number of
GFAP+ cells was quantified in the cerebellar granular layer (CGL). Dot blots represent
mean ± SD GFAP expression, quantified as the percentage of the surface occupied by the
GFAP staining over the total measured area; 10 regions of interest per slice, 4 slices per mouse
and 4 mice per treatment group were used for quantification; two-way ANOVA followed by
Bonferroni’s post-hoc test.
(TIF)
S7 Fig. POM antibodies do not alter AMPA and NMDA receptor clustering. (A) Immunore-
activity of mGluR5s and PSD95 in cultured hippocampal neurons. Threshold images show the
identified clusters. Arrow indicates that synaptic clusters co-localize with mGluR5 clusters. (B)
Representative image (control condition) showing the immunoreactivity of GluR2 subunit of
AMPA receptor following methanol fixation / permeabilization. Scale bar: 2 μm. (C) Quantifica-
tion of the fluorescence intensity indicate that cluster size was not modified following POM anti-
bodies application (One-way ANOVA with Dunnett’s post-hoc test relative to control; field of
view (n): Control-22, POM1-22, POM2-22, POM3-22 from 2-independent experiments). (D)
Representative image (control condition) showing the fluorescence of GluN2A-GFP subunit of
NMDA receptor ~48 h after transfection and paraformaldehyde fixation. Scale bar: 2μm. (E)
Quantification of fluorescence intensity indicate that the cluster size was not modified following
POM antibodies application (One-way ANOVA with Dunnett’s post-hoc test relative to control;
field of view (n): Control-22, POM1-22, POM2-22, POM3-20 from 2-independent experi-
ments). (F) Representative images showing that the spines in mGluR5-SEP transfected neurons
co-localize with the post-synaptic marker, Homer (which is also the scaffold of mGluR5s).
(TIF)
S1 Table. MPEP values (diurnal measurements) in brain and blood samples. MPEP levels
were assessed in blood and brain of mice at two circadian points within a day (light/dark
cycle). The brain-to-plasma ratios were calculated based on this analysis and is represented in
the tables. The upper table contains the levels of MPEP in brain and the lower table contains
the levels of MPEP in blood.
(PDF)
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